PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW127941View Pathway |
drug action
Solriamfetol Action PathwayHomo sapiens
Solriamfetol, also known as Sunosi, is a dopamine and norepinephrine reuptake inhibitor (DNRI). This drug is indicated for the daytime treatment of sleepiness associated with narcolepsy or obstructive sleep apnea. Solriamfetol was given FDA approval in 2019. Solriamfetol weakly binds to dopamine and norepinephrine transporters but not serotonin transporters. Those transporters are called sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter. This makes more dopamine and noradrenaline available in the synapses of the brain. In consequence, the postsynaptic has more of those neurotransmitters available. Norepinephrine and dopamine are important neurotransmitters in sleep-wake regulation. This drug is available as oral tablets.
|
Creator: Daphnee Created On: June 21, 2023 at 12:22 Last Updated: June 21, 2023 at 12:22 |
PW146888View Pathway |
drug action
Solriamfetol Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 19:17 Last Updated: October 07, 2023 at 19:17 |
PW176232View Pathway |
Solriamfetol Predicted Metabolism PathwayHomo sapiens
Metabolites of Solriamfetol are predicted with biotransformer.
|
Creator: Omolola Created On: December 04, 2023 at 13:00 Last Updated: December 04, 2023 at 13:00 |
PW145978View Pathway |
drug action
Somatostatin Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:07 Last Updated: October 07, 2023 at 17:07 |
PW124340View Pathway |
Some pathHomo sapiens
|
Creator: Guest: Anonymous Created On: November 12, 2020 at 19:10 Last Updated: November 12, 2020 at 19:10 |
PW122143View Pathway |
signaling
Sonic Hedgehog (Shh)Mus musculus
|
Creator: Guest: Anonymous Created On: September 13, 2018 at 20:35 Last Updated: September 13, 2018 at 20:35 |
PW091415View Pathway |
signaling
Sonic Hedgehog (Shh) PathwayHomo sapiens
Sonic hedgehog is a protein that in humans is encoded by the SHH ("sonic hedgehog") gene.[5] Both the gene and the protein may also be found notated alternatively as "Shh". Sonic hedgehog is one of three proteins in the mammalian signaling pathway family called hedgehog, the others being desert hedgehog (DHH) and Indian hedgehog (IHH). SHH is the best studied ligand of the hedgehog signaling pathway. It plays a key role in regulating vertebrate organogenesis, such as in the growth of digits on limbs and organization of the brain. Sonic hedgehog is the best established example of a morphogen as defined by Lewis Wolpert's French flag model—a molecule that diffuses to form a concentration gradient and has different effects on the cells of the developing embryo depending on its concentration. SHH remains important in the adult. It controls cell division of adult stem cells and has been implicated in the development of some cancers.
|
Creator: Aidin Foroutannaddafi Created On: August 14, 2018 at 21:44 Last Updated: August 14, 2018 at 21:44 |
PW132587View Pathway |
Sonidegib Drug MetabolismHomo sapiens
Sonidegib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Sonidegib passes through the liver and is then excreted from the body mainly through the kidney.
|
Creator: Ray Kruger Created On: September 21, 2023 at 22:31 Last Updated: September 21, 2023 at 22:31 |
PW146011View Pathway |
drug action
Sonidegib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:11 Last Updated: October 07, 2023 at 17:11 |
PW124070View Pathway |
drug action
Sorafenib Action PathwayHomo sapiens
Sorafenib, marketed as Nexavar, is a drug for the treatment of advanced renal cell carcinoma (primary kidney cancer). It is an inhibitor of the RAF kinase protein and cell surface kinases PDGF-beta receptor, VEGF 2 and 3 receptor (many sources also say VEGFR 1), c-KIT receptor, and FLT-3 receptor. Overall, sorafenib targets the Raf/Mek/Erk pathway. The kinases that are targeting are involved in angiogenesis which reduces blood flow to the tumor and also for genetic transcription for cell proliferation and replication. Sorafenib's mechanism of action works by inhibiting the cell surface kinases, which blocks their signalling to RAF and AKT pathways which are responsible for cell proliferation. C-KIT and FLT-3 on tumor cells are inhibited causing their proliferation to stop and the PDGF and VEGF receptors on endothelial cells are inhibited to stop the growth of new blood vessels that bring blood flow to the tumor. Sorafenib also inhibits RAF1 which is a protein that regulates apoptosis of the cell. With RAF1 blocked, apoptosis is not regulated and can occur. Sorafenib is taken orally in a tablet for and enters the bloodstream through the GI tract to be delivered to the site of action.
|
Creator: Kristen Yee Created On: August 13, 2020 at 10:12 Last Updated: August 13, 2020 at 10:12 |